Newly announced topline results from Eli Lilly’s SURPASS-4 trial program show the company’s investigational diabetes agent, tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes. 

Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.

In a groundbreaking study, scientists at Harvard University identified an enzyme that seems to dictate the limits of human physical performance.

Novo Nordisk is involved in a clinical trial using the company’s GLP-1 analog diabetes drug Victoza to evaluate if the medicine can improve brain function and cognition in Alzheimer’s patients.

Vertex Pharmaceuticals announced a deal to buy Semma Therapeutics, which focuses on using stem cell-derived human islets as a possible cure for type 1 diabetes.

Eli Lilly and Co.’s experimental diabetes treatment Ultra Rapid Lispro was shown to be as effective as the drugmaker’s blockbuster Humalog medicine in two late-stage studies.

Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.

A large organization of internal medicine physicians said adults with type 2 diabetes can aim for an easier-to-achieve blood sugar target than what has been used to guide treatment in the past.